Odanacatib

Odanacatib

Clinical data
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name N-(1-Cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide
Synonyms	(2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
CAS Number	603139-19-1 Y
PubChem CID	10152654
IUPHAR/BPS	6478
ChemSpider	8328162 N
UNII	N673F6W2VH
KEGG	D08955 N
ChEMBL	CHEMBL481611 N
ECHA InfoCard	100.207.747
Chemical and physical data
Formula	C25H27F4N3O3S
Molar mass	525.56 g/mol
3D model (JSmol)	Interactive image
SMILES CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
InChI InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 N Key:FWIVDMJALNEADT-SFTDATJTSA-N N
NY (what is this?)

Odanacatib (INN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.

It is being developed by Merck & Co. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015. In 2014 Cowen and Co predicted odanacatib will generate a billion US$ per year in sales by 2020.

In 2016, Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke.

This drug was developed at Merck Frosst in Montreal.